PPT Slide
Results Summary ‘Other Solid Tumor Trial’ - 011
- No statistical difference for 4 mg for protocol-specified endpoint
- Substantial evidence for 4 mg for Time to First SRE
- Substantial efficacy for 8 mg in both endpoints, i.e. Proportions of Patients with any SRE and for Time to First Event